Ebola virus vaccine displayed in the public health epidemic prevention and anti-epidemic zone
In the public health epidemic prevention and anti-epidemic zone, multinational enterprises showcase diverse work and important progress in supporting the fight against the epidemic. Among them, the most attractive thing is the progress of the development of vaccines and therapeutic drugs. For example: Takeda introduced the plasma-derived therapy that is being developed - antiviral polyclonal hyperimmunoglobulin. This therapy has now begun its first batch production and is used for clinical trials; Takeda also redevelopment and testing of four in-line products; GSK shares experience in vaccine development.
In addition to seeking scientific breakthroughs and solutions, multinational companies are also showing that the anti-epidemic work itself is support and alliance. For example, in a series of work in fighting the epidemic, Novartis has set up a global fund with a total of US$40 million to support communities affected by the epidemic; it has joined hands with 15 life science companies, with the Bill and Melinda Gates Foundation, the Wellcome Foundation and Mastercard to build a cross-continental alliance against the epidemic, accelerate the development of COVID-19 solutions, and promote the access to diagnosis, vaccines and treatment. Dan Brindle, President of Novartis Group (China), said: "We are very pleased to showcase our rich product lines, innovative achievements and solutions at the CIIE, while sharing Novartis' responsibility and actions as a world-leading pharmaceutical and health company in the fight against the epidemic. We also call on the entire industry and across industries to continue to work together to break organizational barriers and jointly curb and end the COVID-19 pandemic."
CIIE has always been an important stage for multinational pharmaceutical companies to showcase their innovative products. This time, major multinational pharmaceutical companies have basically displayed major products covering their core fields, including innovative drugs that have been launched in recent years, and products under development that are expected to be approved in China in the future. These products cover important areas such as tumors, anti-infection, and autoimmunity. It is worth noting that the progress in the field of rare disease has also been brought into in China. For example, Takeda will soon approve many innovative drugs mostly focus on the field of rare disease; Pfizer also brought its innovative drug chlorobenzoic acid soft capsules. After
is increasingly valued by multinational pharmaceutical companies in the Chinese market, the speed of innovative products entering China is also accelerating. For example, in 2020, Takeda will have nearly 7 innovative drugs on the market in China; from 2020 to 2024, Novartis is expected to submit 50 new drug applications in China; BMS will introduce nearly 30 innovative products or indications in China in the next five years. Boehringer Ingelheim also officially announced a five-year plan for China to expand its investment of 451 million euros on the eve of the CIIE.
In addition, on the exchange platform of the CIIE, the launch and signing of various cooperations are also very active, including various diagnosis and treatment centers that promote innovation implementation, cooperation in exploring innovative payment models, and cooperation in exploring new technologies such as digital innovation and artificial intelligence.
booth highlights
AstraZeneca : It will take "China headquarters plus five regional headquarters" as the main line, and present a new layout in China for the first time at the booth. A number of signing events will also be held on site, the latest progress of the global medical industry fund will be announced, and the latest cooperation intentions will be announced with multiple strategic partners.
Bayer : The theme of the booth is "Share health, eliminate hunger", showing Bayer's core competitiveness in the fields of medical health and agriculture. In terms of products, Bayer showed Dofigo, a radioactive drug approved for the treatment of prostate cancer in China in August this year, and the world's first intelligent magnetic resonance high-pressure contrast injection system, MRXperion.
Boehringer Ingelheim : After the first proposed the concept of full-course management of stroke at the last CIIE, Boehringer Ingelheim will fully demonstrate its "stroke full-course solution" at this CIIE, covering all aspects of stroke diseases such as stroke prevention, testing, first aid, diagnosis, treatment, rehabilitation, prevention of recurrence and disease education.Including introducing its thrombolytic products for injection alteplase and the stroke rehabilitation project "Jida Rehabilitation". In addition, Boehringer Ingelheim's first classic live swine fever vaccine developed in China will be unveiled at the third CIIE. This is the first live swine fever vaccine product in the Chinese market developed by multinational companies and domestic research institutes.
Bristol-Myers Squibb : In the booth layout, it demonstrates its innovative concept through three robotic arm-driven screens and their projected contents in an innovative Industry 5.0 way. It also introduces BMS's future plans to introduce a series of innovative products from China through the "Wings of Innovation" interactive device area, including "Immune Gemini" and multiple research and development products in the field of hematology and immunology that have been shown to the public for the first time.
GlaxoSmithKline : Showcased dozens of innovative products, including herpes zoster vaccine Xin'anlishi, systemic lupus erythematosus drug Beliteng, COPD treatment drug Quan Zaile and HIV drug Dovato, which is expected to be approved in China in 2020. At the same time, in the anti-epidemic area, advanced experience in the vaccine field was shared.
Pfizer : Displays a number of innovative products, including Vivanxin, a rare disease innovative drug for the treatment of ATTR-CM, two major oncology innovative drugs, CD22 antibody-conjugated drug (ADC), Bebosa, the third-generation ALK-targeted drug loratinib, the innovative dermatologic drug Shutanming, which was approved in China at the end of July, and three vaccines - the 13-valent pneumococcal polysaccharide binding vaccine that explores the expansion of indications, the 20-valent pneumococcal binding vaccine that released the latest research data, and the first innovative tetravalent meningococcal binding vaccine to be launched in China.
Novartis : In terms of innovative products, the company showed nearly 60 main products approved in China in recent years, covering more than 10 major disease fields; as well as multiple products or new indications that are expected to be introduced in China, including new drugs for cardiovascular diseases, central nervous system and rare diseases, and multiple major anti-tumor drugs. Novartis also demonstrated its work in cooperating with many medical institutions and associations to build standardized disease diagnosis and treatment centers. For example, more than 300 "Heart Failure Centers" jointly built by Novartis have completed certification, more than 1,300 registered hospitals, and the "Psoriatic Standardized Diagnosis and Treatment Center" has covered 150 hospitals, and the "Bright Center" is expected to be built in 2021.
Novo Nordisk : Showcases 14+9+3 innovative products and injection devices and innovative digital medical solutions. It includes the world's only soluble double insulin - Degu Astor double insulin injection Nohejia; China's only anti-glycemic drug with cardiovascular indications - Liraglutide injection Noheli; and Degu Insulin injection Noheli, which has rapid review and rapid medical insurance.
Xi'an Jansen : In terms of innovative products, the company brings interleukin 23 inhibitor Tenoya (Gusecchiuzumab injection); CD38 monoclonal antibody Zhaoke (Daretouzumab injection); biologic preparation for treating psoriasis Starano (Usinumumab), and China's first new generation androgen receptor inhibitor Ansenko (Apataminamide tablets) approved for non-metastatic castration-resistant prostate cancer patients.
In addition, for the field of mental health, Xi'an Jansen will hold a "Share Conference on Mental Health Peer Support and Community Mental Health Service Capacity Improvement Project", inviting top experts to discuss innovative service models in the field of mental health. At the same time, in the public health epidemic prevention and epidemic prevention exhibition area, Xi'an's work in the field of mental health is fully displayed.
Msodym : In the epidemic prevention area, three research plans and progress were displayed in the fight against the new coronavirus. Including cooperating with Ridgeback Bio to develop antiviral drugs, conducting phase II and phase III clinical practices in some regions, and acquiring Themis Bioscience. The new coronavirus vaccine developed based on the measles virus vector platform has entered the phase I clinical trial; cooperating with IAVI to develop the new coronavirus vaccine, which is about to enter the phase I clinical trial.
MX Online Booth
Sanofi : Four exhibition areas introduce the achievements of innovative therapies, chronic disease health management, protecting public health with innovative vaccines and jointly building a digital health ecology, and showcase 14 breakthrough innovative products of Sanofi, including 7 first-time products - anti-arrhythmic drug Medalon; Zenon; CD38 monoclonal antibody Isatuximab; three rare disease treatment products Venglustat, Fitusiran and BTKi (’168); and the world's first FDA-approved tetanus toxin-based tetanus conjugate vaccine MenquadfiT. In addition, Sanofi proposed the overall concept of China's future smart public health ecosystem, as well as the core modules of the system designed and developed based on the latest research results, mainly including smart public health city management platform, public-funded vaccination plan for infectious diseases, full-life vaccination plan and smart unmanned vaccination pods and other innovative solutions.
Takeda : In terms of innovative products, Takeda showed the blockbuster products approved in China in recent years Enlaire®, Walker®, Anshili®, Anjiyou®, Ripjia®, and Flexbumin®; the upcoming products are mainly concentrated in the fields of rare diseases, including lanaliazumab injection, etibante injection, veraginase α, and myPKFiT. Takeda will also showcase its innovative achievements in the fight against the epidemic, including the formation of the CoVIg-19 plasma alliance and the cooperation in the development of potential plasma-derived therapies for adult hospitalized patients with novel coronavirus pneumonia who may experience serious complications; redevelopment and testing of four in-line products for the treatment of COVID-19 patients.
Eli Lilly: This year, Eli Lilly’s booth has expanded 4 times, and the 300-square-meter main booth shows Eli Lilly’s innovative strength and determination to cultivate China in all aspects. It is understood that its main booth will display its major innovative product in the field of tumors - Xindilizumab injection, a PD-1 product developed in cooperation with Innovent Biologics. In addition, Eli Lilly will also display the breast cancer targeted drug Abecili, which has not been approved in China, as well as the new drug Duyida (Dula glycopeptide), a new drug for rheumatoid arthritis Alomine (Baretinib tablets), and a new drug for psoriasis Tuozhi (Echilizumab injection), etc. On November 8, Mr. Dai Jialing, co-founder and publisher of R&D, will also attend the seminar on "Sinization of Global Innovation in the Biopharmaceutical Era" held by the "Healthy Shanghai Studio" during the CIIE. He will discuss the strategic development of China's drug research and development globalization strategy with Dr. Wang Li, Senior Vice President and Head of Drug Development and Medical Affairs of Eli Lilly China, Conway, Executive President of the Drug Development and Development Industry Committee (RDPAC), and Shi Yi, managing partner of Eli Lilly Asia Fund, to discuss the strategic development of China's drug research and development globalization (please see the poster for registration) .
Photography | Tang Yanjun Liu Yilin
Total No. 1169
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-